Cancer - Advances, Knowledge, Integrative & Holistic Treatments
20.0K views | +0 today
Follow
Cancer - Advances, Knowledge, Integrative & Holistic Treatments
Your new post is loading...
Your new post is loading...
Scooped by Graham Player Ph.D.
Scoop.it!

Rate and Risk of Mesothelioma Increases Over Many Years After Initial Exposure to Asbestos

Rate and Risk of Mesothelioma Increases Over Many Years After Initial Exposure to Asbestos | Cancer - Advances, Knowledge, Integrative & Holistic Treatments | Scoop.it
Mesothelioma risk endures over long-term
Graham Player Ph.D.'s insight:

Pleural and peritoneal mesothelioma are cancers that develop on the lining of the lungs and are almost always caused by asbestos exposure.

The Curtin University and UWA School of Public Health in Australia investigated 22,048 people exposed to asbestos across the globe. They found the rate and risk of pleural mesothelioma increased until 45 years after the first exposure. After 45 years the risk rate then appeared to slow down. However, the rate of peritoneal mesothelioma over 10-50 years continued to increase.

No comment yet.
Scooped by Graham Player Ph.D.
Scoop.it!

Gene Discovered That May Lead to Stopping Metastasis in Lung Cancer, Mesothelioma and Other Cancers

Gene Discovered That May Lead to Stopping Metastasis in Lung Cancer, Mesothelioma and Other Cancers | Cancer - Advances, Knowledge, Integrative & Holistic Treatments | Scoop.it
Graham Player Ph.D.'s insight:

In a study at the Salk Institute, Reuben Shaw, Professor of Molecular & Cell Biology says they have discovered a new anti-cancer gene that stops the spread of tumor cells throughout the body.

The Salk researchers realized that when lung cancer patients have an alteration in the LKB1 gene their tumors metastasized at a “much greater rate.” They then determined that LKB1 is capable of calling on another gene, DIXDC1, to manipulate the focal adhesions, freeing cancer cells to move about. LKB1, in effect, deactivated the standard workings of DIXDC1 that held the cells in place.

The researchers tested two methods to stop the communication between the two genes: block DIXDC1 directly, and delete LKB1. What they found instead was that by reactivating DIXDC1 cancer metastasis slowed.

Shaw noted that currently there are no treatments for cancers with mutations in LKB1 or DIXDC1. He believes treatments targeted to these two genes could be effective.

 

No comment yet.
Scooped by Graham Player Ph.D.
Scoop.it!

Curcumin Together With Cancer Inhibiting Peptides Shown to Reduce Cancer Severity in Mesothelioma

Curcumin Together With Cancer Inhibiting Peptides Shown to Reduce Cancer Severity in Mesothelioma | Cancer - Advances, Knowledge, Integrative & Holistic Treatments | Scoop.it

PIAS3 levels, which brought down STAT3 activity and caused mesothelioma cells to die. Their study served as proof of principle about the effectiveness of these two compounds in treating malignant mesothelioma, a first step in moving a treatment toward clinical trials.

Graham Player Ph.D.'s insight:

The culprit in sparking many cancers, particularly mesothelioma, is the intracellular protein and transcription factor STAT3 (signal transducer and activator of transcription 3). A signal transducer and activator is a pathway for instructing the growth and survival of cells, and a transcription factor is a protein that controls genetic information directing cells how to perform. STAT3 is notorious for sending signals to trigger the onset of human cancers and to fuel their continued growth.

The great neutralizer of STAT3 is PIAS3 (protein inhibitor of activated STAT3). PIAS3 possesses the strength to inhibit and block STAT3's ability to cause cancer. Scientists from Case Western Reserve University and the Georg-Speyer-Haus in Frankfurt, Germany, demonstrated that application of curcumin, a derivative of the spice turmeric, and cancer-inhibiting peptides increase PIAS3 levels, which brought down STAT3 activity and caused mesothelioma cells to die.

Their study served as proof of principle about the effectiveness of these two compounds in treating malignant mesothelioma, a first step in moving a treatment toward clinical trials.

No comment yet.